A Biomedical Engineer specialising in glaucoma research has joined the Axenfeld-Rieger Foundation’s Scientific Advisory Board.
Dr. Ross Ethier is a multidisciplinary researcher and a Professor at Georgia Tech. His research focuses on understanding the biomechanics of aqueous humour drainage, and the eye’s mechanical and cellular response to intraocular pressure.
He brings more than 20 years of glaucoma research to the team.
“I am pleased to join the Advisory Board and contribute to a deeper understanding of this condition that affects the vision of young people around the world”, Ethier stated. “I particularly look forward to working with Ms. Sloan and other team members to advise on the development of therapies to help Axenfeld-Rieger patients”.
“I am very excited to welcome Dr. Ethier to the team,” said Rebecca Sloan, founder of the Axenfeld-Rieger Foundation. “We know that cells and tissues within eyes affected by Axenfeld-Rieger Syndrome are different, and stiffer, than those unaffected by the condition. Dr Ethier’s knowledge of how these changes can impact how the eye functions will be of enormous importance in our efforts to design an effective glaucoma treatment for this rare disease.”
Dr Ross Ethier is a Professor in the Wallace H. Coulter Department of Biomedical Engineering, the Lawrence L. Gellerstedt Jr. Chair in Bioengineering, and a Georgia Research Alliance Eminent Scholar. He is the Principal Investigator at Georgia Tech’s Ethier Lab.
The Axenfeld-Rieger Foundation is a patient advocacy group dedicated to improving the lives of patients. Its focus is on advancing scientific research into the condition and developing a cure for the glaucoma caused by Axenfeld-Rieger Syndrome.
Geneticists studying ocular and craniofacial development join Axenfeld-Rieger Foundation’s Scientific Advisory Board
